NovoCure Ltd [NASDAQ: NVCR] closed the trading session at $29.85.
The stocks have a year to date performance of 99.93 percent and weekly performance of 68.36 percent. The stock has been moved at 24.95 percent over the last six months. The stock has performed 96.64 percent around the most recent 30 days and changed 78.21 percent over the most recent 3-months.
If compared to the average trading volume of 1.04M shares, NVCR reached to a volume of 12202057 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about NovoCure Ltd [NVCR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVCR shares is $31.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVCR stock is a recommendation set at 1.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for NovoCure Ltd shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on Dec-03-24. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $24 to $30. The new note on the price target was released on October 16, 2024, representing the official price target for NovoCure Ltd stock. Previously, the target price had yet another raise to $15, while JP Morgan analysts kept a Neutral rating on NVCR stock. On August 28, 2023, analysts decreased their price target for NVCR shares from 85 to 25.
The Average True Range (ATR) for NovoCure Ltd is set at 1.85, with the Price to Sales ratio for NVCR stock in the period of the last 12 months amounting to 5.69. The Price to Book ratio for the last quarter was 8.94, with the Price to Cash per share for the same quarter was set at 8.75.
NVCR stock trade performance evaluation
NovoCure Ltd [NVCR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 68.36. With this latest performance, NVCR shares gained by 96.64% in over the last four-week period, additionally plugging by 24.95% over the last 6 months – not to mention a rise of 143.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVCR stock in for the last two-week period is set at 83.96, with the RSI for the last a single of trading hit 89.02, and the three-weeks RSI is set at 79.26 for NovoCure Ltd [NVCR]. The present Moving Average for the last 50 days of trading for this stock 16.85, while it was recorded at 21.25 for the last single week of trading, and 17.27 for the last 200 days.
NovoCure Ltd [NVCR]: An insightful look at the core fundamentals
NovoCure Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.44 and a Current Ratio set at 1.49.
NovoCure Ltd [NVCR]: Institutional Ownership
There are presently around $86.67%, or 95.52%% of NVCR stock, in the hands of institutional investors. The top three institutional holders of NVCR stocks are: FMR LLC with ownership of 16.14 million shares, which is approximately 15.0482%. BLACKROCK INC., holding 12.13 million shares of the stock with an approximate value of $$207.83 million in NVCR stocks shares; and BLACKROCK INC., currently with $$200.36 million in NVCR stock with ownership which is approximately 10.904%.
